Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

Tirzepatide 10 mg

$179Per Unit

Lyophilized dual incretin mimetic peptide with verified sequence, high-resolution HPLC chromatogram, and mass spectrometry documentation. Stored under validated cold chain conditions.

Lot TRZ2026-01A · COA on request
Lyophilized dual agonist peptide, sterile stoppered vial, 10 mg fill
2–8°C (stable 30 days)

5 × $179.00 = $895.00 $581.75 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

Tirzepatide 10 mg

$581.75 for 5 · 35% off

Research use only
Tirzepatide 10 mg research packaging
Lyophilized dual agonist peptide, sterile stoppered vial, 10 mg fill
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot TRZ2026-01A) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

Tirzepatide(LY3298176)

Regulatory status
FDA-approved medicine: Mounjaro (type 2 diabetes, May 2022) and Zepbound (chronic weight management, Nov 2023).
Strongest evidence
Approved drug backed by large phase 3 trials
Overview

Tirzepatide is a once-weekly peptide that activates GIP and GLP-1 receptors. It is marketed by Eli Lilly as Mounjaro and Zepbound.

What researchers study it for
  • Type 2 diabetes
  • Obesity and overweight
  • Weight-related conditions studied in later trials
Mechanism

Dual agonist of the GIP and GLP-1 receptors - incretin hormones that act on insulin secretion, glucagon, gastric emptying and appetite.

Evidence (2)
  1. Human · randomized trial

    SURMOUNT-1 (phase 3, NEJM 2022)

    2,539 adults with obesity or overweight without diabetes, 72 weeks. Mean weight change was −15.0%, −19.5% and −20.9% across the three doses versus −3.1% with placebo. Gastrointestinal adverse events were the most common and mostly mild to moderate.[1]

  2. Approved drug

    FDA approvals

    Approved as Mounjaro on May 13, 2022 and as Zepbound on Nov 8, 2023 (Drugs@FDA).[2][3]

Limitations of the evidence
  • Trial results describe the approved medicine in defined patient populations.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Questions researchers ask
Is tirzepatide the same as retatrutide?
No. Tirzepatide activates two receptors (GIP, GLP-1); retatrutide also activates the glucagon receptor and is still investigational.
Sources (3)
  1. 1.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff AM et al. N Engl J Med. 2022 Human · randomized trial
  2. 2.Mounjaro (tirzepatide) - original approval 2022-05-13Drugs@FDA, NDA 215866 Approved drug
  3. 3.Zepbound (tirzepatide) - original approval 2023-11-08Drugs@FDA, NDA 217806 Approved drug
Every published studyPubMed search: Tirzepatide(opens in a new tab)Every registered trialClinicalTrials.gov search: Tirzepatide(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.